Screener
Wave Life Sciences WVE Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Amortization of right-of-use assets | 2,975 | 2,620 |
| Depreciation of property and equipment | 1,699 | 1,740 |
| Accretion of investment premium | (65) | — |
| Share-based compensation expense | 19,796 | 11,149 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 388 | (195) |
| Prepaid expenses | (3,726) | 2,844 |
| Other assets | (1,473) | (81) |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's stock-based comp?
- Wave Life Sciences (WVE) reported stock-based comp of $10.73M in Q2 2026.
- How has Wave Life Sciences's stock-based comp changed year-over-year?
- Wave Life Sciences's stock-based comp increased by 73.2% year-over-year, from $6.2M to $10.73M.
- What is the long-term trend for Wave Life Sciences's stock-based comp?
- Over 4 years (2021 to 2025), Wave Life Sciences's stock-based comp has grown at a 11.1% compound annual growth rate (CAGR), from $16.41M to $24.97M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Wave Life Sciences's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude